WO2003080036A2 - Utilisation d'un vanilloide comme anti-ronflement - Google Patents
Utilisation d'un vanilloide comme anti-ronflement Download PDFInfo
- Publication number
- WO2003080036A2 WO2003080036A2 PCT/FR2003/000936 FR0300936W WO03080036A2 WO 2003080036 A2 WO2003080036 A2 WO 2003080036A2 FR 0300936 W FR0300936 W FR 0300936W WO 03080036 A2 WO03080036 A2 WO 03080036A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- shogaol
- advantageously
- vanilloid
- use according
- extract
- Prior art date
Links
- PETRWTHZSKVLRE-UHFFFAOYSA-N Cc(cc1)cc(OC)c1O Chemical compound Cc(cc1)cc(OC)c1O PETRWTHZSKVLRE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- TITLE USE OF A VANILLOID AS ANTI-SNORING
- the present invention relates to novel compositions useful against snoring and sleep apnea. It relates in particular to the use of a vanilloid to prevent, reduce or suppress snoring.
- snoring is not considered a health problem. In general it does not annoy the person who snores, but can considerably annoy those around him. Snoring is more common in men (20 to 32%) than women (8%) (Jennum P et al., J Sleep Res., 1992, 1, p.240-244 and Teculescu et al., Respiration 2001 , 68 (4 ⁇ p.365- 370), and more in obese people than thin people.
- the typical noise of snoring occurs when the soft tissues of the upper respiratory tract vibrate with the passage of air, which can be caused by one or more of four different situations:
- a polyp is a longiform growth which occurs on a mucous membrane
- Certain medications such as antihistamines or hypnotics can cause your throat muscles to relax too much and make snoring easier.
- Sleep apnea consists of more or less long, more or less followed respiratory stops, after which breathing resumes with noise. It is a problem that causes fatigue, mood swings, depression and even heart problems due to poor sleep and the dangerous drop in blood pressure.
- snoring problems are mainly treated by surgery which aims to modify the topology of the upper airways (veloplasty, somnoplasty, somnoplasty by injection etc.).
- veloplasty, somnoplasty, somnoplasty by injection etc. There are also various accessories supposed to come to the aid of snorers: pillows to better position the head, nasal orthosis to keep the air passage open etc.
- Some products to treat snoring problems are also available, in particular essential oils but without much success (WO 00/25588).
- a vanilloid can be used to prevent, suppress or decrease snoring and to treat sleep apnea.
- Gingerol another member of the vanilloid family, is also known to be a constituent of ginger belonging to the Zingiber officinalis family.
- Anti-snoring compositions comprising as main components an extract of Zingiber officinale and Dioscorea (Dioscorea villosa or Dioscoreaceae among others) have also been described (US 5,565,201, US 5,603,935, US 5,804,211).
- Zingiber officmale extract has never been described as having an action against snoring on its own. On the contrary, the presence of the second component seems essential (synergy of actions).
- the vanilloids alone can be active anti-snoring.
- the present invention therefore relates to the use of a vanilloid to reduce, suppress or prevent snoring.
- vanilloid means any chemical molecule corresponding to any one of the following general formulas:
- X represents a linear, saturated, mono-unsaturated or polyunsaturated, substituted or unsubstituted C ⁇ -C 4 alkyl group
- Y is chosen from the groups -N (H) C (O) -, -C (O) N-, and -C (O) -;
- RI represents a linear, branched or cyclic chain, saturated, monounsaturated or polyunsaturated, substituted or unsubstituted C 2 -C 24 alkyl group.
- the vanilloid is chosen from the group consisting of capsaicin, piperine, gingerols and shogaols.
- it is one or more shogaols.
- the present invention relates to the use of a vanilloid for the manufacture of a medicament for treating sleep apnea.
- capsaicin corresponds to the following general formula:
- the capsicum fruit powder is obtained by percolation of the capsicum fruit powder and then purification of the capsicin thus obtained. It is also commercially available.
- the piperine is obtained by extraction of the pericarp from the black pepper. It is also commercially available.
- the shogaol (s) correspond (s) to the general formula (III):
- n is equal to 1, 2, 4, 6 or 8 and which are respectively named [3] - shogaol, [4] -shogaol, [6] -shogaol, [8] -shogaol and [10] -shogaol. Even more advantageously, it is [3] -shogaol.
- the shogaol (s) are in the form of a crude extract of a plant of the family Zingiberaceae, advantageously by a process which comprises the following step: a) preparation of crude extract from rhizomes, fresh or dried, of said plant, by maceration of a ground material of these rhizomes at a temperature between 10 and 35 ° C, followed by one or more reflux extractions of this ground material, or by subjecting a ground material of said rhizomes to percolation at a temperature between 10 and 35 ° C, each of these operations (maceration, reflux extractions and percolation) being carried out using an organic solvent or a mixture of appropriate organic solvents .
- the maceration of the ground rhizomes, prior to its extraction, has the main effect of improving the contacting of the plant tissues and the solvent during the extraction. Its duration can be between a dozen hours and a week depending on the state of freshness of the rhizomes used.
- organic solvents are used which are miscible with water and have a relatively low boiling point so that they can be easily removed later by simple evaporation. , such as ethanol, methanol, acetone or their mixtures with water.
- shogaols are soluble in many organic solvents, it is also other organic solvents such as ethyl acetate, ethyl ether, chloroform or methylene chloride can be used.
- the shogaol (s) are in the form of a purified extract of a plant of the family Zingiberaceae, advantageously obtained by a process which comprises, in addition to step a) described below above, the following additional steps: b) purification of the crude extract obtained in step a) by subjecting said extract, after elimination of the solvent or solvents which it contains and its recovery in water, to one or more several extractions against the current using an organic solvent or a mixture of organic solvents immiscible with water and, if desired, c) cliromatographic separation of the shogaols.
- the water-immiscible organic solvent (s) useful for carrying out the counter-current extractions of the crude extract with a view to its purification are, in particular, chosen from ethyl acetate, ethyl ether, chloroform , methylene chloride and mixtures thereof.
- the plant of the family Zingiberaceae is chosen from the species Alpinia galanga, Alpinia officinarum, Zingiber officinalis, Zingiber cassumunar and Zingiber zerumbet, even more advantageously, it is / Alpinia galanga.
- [3] -shogaol, [6] -shogaol and [8] -shogaol can be extracted from plants of the genus Alpinia such as Alpinia galanga or Alpinia officinarum, while [4] -shogaol and [10] -shogaol can be extracted from plants of the genus Zingiber such as Zingiber officinalis, Zingiber cassumunar or Zingiber zerumbet, in particular using the method as described above.
- the crude extract from Alpinia galanga contains an amount of [3] - shogaol comprised by weight between approximately 1 to 5% of the dry weight of said extract.
- this extract is obtained from rhizomes, fresh or dry, of said plant.
- the purified extract & Alpinia galanga contains an amount of [3] -shogaol at least equal by weight to 75% of the dry weight of said extract.
- the present invention also relates to the use of a vanilloid for the preparation of an anti-snoring composition.
- the anti-snoring composition is formulated for oral administration, for example, in the form of powders, solutions or oral suspensions, syrups, tablets or capsules.
- composition is formulated in the form of a nasal or oral spray.
- Physiologically acceptable excipients can be used in this type of composition. These excipients are conventional and well known to those skilled in the art.
- the vanilloid is used at a daily dose corresponding to 20 mg of vanilloid taken in the form of plant extract or pure vanilloid.
- it is in this case shogaol.
- Example 1 Preparation of a crude extract of rhizomes of Alpinia galanga
- a kilo of fresh rhizomes tf Alpinia galanga is coarsely ground, taking care not to cause excessive heating of the ground parts.
- the water content of the ground product thus obtained is determined and it is macerated in 7 liters of ethanol, the title of which is chosen so that, taking into account the water content of the ground material, the maceration solvent is 50% ethanol.
- the ground material is extracted at reflux with the maceration solvent for 30 minutes. This solvent is removed and replaced with an equal weight of 50% ethanol, and the ground material is again extracted at reflux for 30 minutes. The operation is repeated once.
- the 3 extracts obtained are combined (thus constituting a volume of about 19 liters), filtered on paper, then evaporated to dryness under reduced pressure.
- a residue is obtained which weighs approximately 50 g, ie an approximate yield of 30% relative to the dry weight of the rhizomes.
- This extract contains the different shogaols present in the rhizomes of Alpinia galanga ([3] -shogaol, [6] -shogaol and [8] -shogaol) and its [3] -shogaol content is generally between 1 and 5% (w / w) depending on the rhizomes used.
- [3] -shogaol can be obtained from Alpinia galanga rhizomes by preparing a crude extract of these rhizomes in accordance with Example 1, then purifying this extract in accordance with Example 2 and then subjecting the extract thus purified by successive elutions on columns of silica gel, for example in the following manner. 10 g of a purified extract, prepared in accordance with Example 2, are added with 100 g of silica gel G60 and 500 ml of chloroform with constant stirring. As soon as this mixture is homogeneous, it is evaporated to dryness under reduced pressure so as to obtain a powder.
- This powder is deposited at the top of a column 10 cm in diameter and 50 cm in height, also containing G60 silica gel in petroleum ether.
- the chloroform phase is evaporated to dryness under reduced pressure, leaving room for a residue of approximately 2.3 g.
- This residue is then subjected to preparative chromatography on a column 5 cm in diameter and 20 cm in height, filled with Cl 8 silica gel, and using a water / acetonitrile mixture (70/30) as elution gradient. .
- the fraction containing [3] -shogaol is eluted in a time between 5 and 7 minutes for a flow rate of 30 ml / min.
- [3] -shogaol can be identified by high pressure liquid chromatography (HPLC) coupled with mass spectrometry.
- HPLC high pressure liquid chromatography
- This powder was then distributed in No. 0 capsules so as to obtain a unit dosage of 250 mg of crude extract.
- capsules can be made from [3] -shogaol to obtain a unit dosage of 25 mg of [3] -shogaol.
- Example 5 activity of shogaol on snoring:
- Shogaol significantly reduces snoring in users.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/509,048 US20050118287A1 (en) | 2002-03-25 | 2003-03-25 | Use of a vanilloid as an anti-snoring element |
AU2003244710A AU2003244710A1 (en) | 2002-03-25 | 2003-03-25 | Use of a vanilloid as an anti-snoring element |
EP03738193A EP1487425A2 (fr) | 2002-03-25 | 2003-03-25 | Utilisation d un vanilloide comme anti-ronflement |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0203681A FR2837390A1 (fr) | 2002-03-25 | 2002-03-25 | Utilisation d'un vanilloide comme anti-ronflement |
FR02/03681 | 2002-03-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003080036A2 true WO2003080036A2 (fr) | 2003-10-02 |
WO2003080036A3 WO2003080036A3 (fr) | 2004-02-19 |
WO2003080036B1 WO2003080036B1 (fr) | 2004-04-15 |
Family
ID=27799229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/000936 WO2003080036A2 (fr) | 2002-03-25 | 2003-03-25 | Utilisation d'un vanilloide comme anti-ronflement |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050118287A1 (fr) |
EP (1) | EP1487425A2 (fr) |
AU (1) | AU2003244710A1 (fr) |
FR (1) | FR2837390A1 (fr) |
WO (1) | WO2003080036A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007047575A2 (fr) * | 2005-10-14 | 2007-04-26 | The Board Of Trustees Of The University Of Illinois | Traitements pharmacologiques contre des troubles du sommeil |
EP2138054A1 (fr) | 2008-06-26 | 2009-12-30 | Léon Cariel | Extrait de plante pour la prévention ou le traitement du ronflement et/ou de l'apnée du sommeil |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2574898C (fr) * | 2004-07-23 | 2011-12-20 | Tsung-Chung Lin | Activite immunomodulatrice et anti-allergique de zingiber zerumbet |
EP1870136A1 (fr) * | 2006-06-12 | 2007-12-26 | Chanel Parfums Beauté | Utilisation cosmétique d'une cassumunarine, d'un arylbutenoide et/ou d'un extrait botanique en contenant |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0646372A1 (fr) * | 1993-09-30 | 1995-04-05 | Medichemie Ag | Médicament à base de capsaicine pour le traitement de la rhinopathie chronique |
US5565201A (en) * | 1995-02-25 | 1996-10-15 | Li; Hongzhi | Pharmaceutical composition and preparation for the treatment of snoring and the use thereof |
US5603935A (en) * | 1995-07-29 | 1997-02-18 | Eastern Europe, Inc. | Composition for the treatment of snoring and methods of use thereof |
FR2758086A1 (fr) * | 1997-01-09 | 1998-07-10 | Daniel Jean | Shogaols pour l'utilisation comme medicaments, produits cosmetiques et produits dietetiques, procede d'obtention desdits shogaols et extraits vegetaux les contenant |
US5804211A (en) * | 1996-06-05 | 1998-09-08 | Health Pharm Usa, Inc. | Composition and method for suppressing or eliminating snoring |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187318B1 (en) * | 1998-10-29 | 2001-02-13 | Innovative Chemical Corporation | Anti-snoring composition |
-
2002
- 2002-03-25 FR FR0203681A patent/FR2837390A1/fr active Pending
-
2003
- 2003-03-25 WO PCT/FR2003/000936 patent/WO2003080036A2/fr not_active Application Discontinuation
- 2003-03-25 US US10/509,048 patent/US20050118287A1/en not_active Abandoned
- 2003-03-25 AU AU2003244710A patent/AU2003244710A1/en not_active Abandoned
- 2003-03-25 EP EP03738193A patent/EP1487425A2/fr not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0646372A1 (fr) * | 1993-09-30 | 1995-04-05 | Medichemie Ag | Médicament à base de capsaicine pour le traitement de la rhinopathie chronique |
US5565201A (en) * | 1995-02-25 | 1996-10-15 | Li; Hongzhi | Pharmaceutical composition and preparation for the treatment of snoring and the use thereof |
US5603935A (en) * | 1995-07-29 | 1997-02-18 | Eastern Europe, Inc. | Composition for the treatment of snoring and methods of use thereof |
US5804211A (en) * | 1996-06-05 | 1998-09-08 | Health Pharm Usa, Inc. | Composition and method for suppressing or eliminating snoring |
FR2758086A1 (fr) * | 1997-01-09 | 1998-07-10 | Daniel Jean | Shogaols pour l'utilisation comme medicaments, produits cosmetiques et produits dietetiques, procede d'obtention desdits shogaols et extraits vegetaux les contenant |
Non-Patent Citations (19)
Title |
---|
BAUDOIN T ET AL: "Capsaicin significantly reduces sinonasal polyps." ACTA OTO-LARYNGOLOGICA. NORWAY MAR 2000, vol. 120, no. 2, mars 2000 (2000-03), pages 307-311, XP008022518 ISSN: 0001-6489 * |
CLIFFORD P S ET AL: "PULMONARY DEPRESSOR REFLEX ELICITED BY CAPSAICIN IN CONSCIOUS INTACT AND LUNG-DENERVATED DOGS" AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 252, no. 2, PART 2, 1987, pages 394-397, XP008021980 ISSN: 0002-9513 * |
CORDELL G A ET AL: "CAPSAICIN: IDENTIFICATION, NOMENCLATURE, AND PHARMACOTHERAPY" ANNALS OF PHARMACOTHERAPY, XX, XX, vol. 27, no. 3, 1 mars 1993 (1993-03-01), pages 330-336, XP000604000 ISSN: 1060-0280 * |
DATABASE MEDLINE [en ligne] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; mars 1998 (1998-03) ELSHERIF I ET AL: "The effect of nasal surgery on snoring." Database accession no. NLM9578923 XP002256963 & AMERICAN JOURNAL OF RHINOLOGY. UNITED STATES 1998 MAR-APR, vol. 12, no. 2, mars 1998 (1998-03), pages 77-79, ISSN: 1050-6586 * |
DATABASE MEDLINE [en ligne] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; novembre 1986 (1986-11) SUEKAWA M ET AL: "ÄPharmacological studies on ginger. V. Pharmacological comparison between (6)-shogaol and capsaicin]" Database accession no. NLM3817651 XP002256080 & NIPPON YAKURIGAKU ZASSHI. JAPANESE JOURNAL OF PHARMACOLOGY. JAPAN NOV 1986, vol. 88, no. 5, novembre 1986 (1986-11), pages 339-347, ISSN: 0015-5691 * |
FRIBERG D ET AL: "Abnormal afferent nerve endings in the soft palatal mucosa of sleep apnoics and habitual snorers." REGULATORY PEPTIDES. NETHERLANDS 23 JUL 1997, vol. 71, no. 1, 23 juillet 1997 (1997-07-23), pages 29-36, XP002256079 ISSN: 0167-0115 * |
HAXHIU M A ET AL: "Influence of respiratory drive on airway responses to excitation of lung C-fibers." JOURNAL OF APPLIED PHYSIOLOGY (BETHESDA, MD.: 1985) UNITED STATES JUL 1989, vol. 67, no. 1, juillet 1989 (1989-07), pages 203-209, XP008022529 ISSN: 8750-7587 * |
HEDNER J ET AL: "CAPSAICIN AND REGULATION OF RESPIRATION: INTERACTION WITH CENTRAL SUBSTANCE P MECHANISMS" JOURNAL OF NEURAL TRANSMISSION, SPRINGER VERLAG, VIENNA, AT, vol. 61, no. 3/4, 1985, pages 239-252, XP008010416 ISSN: 0300-9564 * |
KANAMARU, ARATA ET AL: "Respiratory and cardiovascular reflexes elicited by nasal instillation of capsaicin to anesthetized, spontaneously breathing dogs" JOURNAL OF VETERINARY MEDICAL SCIENCE, vol. 63, no. 4, 2001, pages 439-443, XP008010414 * |
KOPCZYNSKA B ET AL: "APNOEIC RESPONSES TO PULMONARY AND SYSTEMIC CHALLENGE OF CAPSAICIN IN CATS" JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, POLISH PHYSIOLOGICAL SOCIETY, KRAKHAW, PL, vol. 49, no. 1, mars 1998 (1998-03), pages 25-35, XP008010415 ISSN: 0867-5910 * |
MARABINI S ET AL: "BENEFICIAL EFFECTS OF INTRANASAL APPLICATIONS OF CAPSAICIN IN PATIENTS WITH VASOMOTOR RHINITIS" EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 248, no. 4, 1991, pages 191-194, XP000603518 ISSN: 0937-4477 * |
MITCHELL H W ET AL: "REFLEX CHANGES IN RESPIRATION AND HEART RATE EVOKED BY INTRAVENOUS AND LEFT VENTRICULAR INJECTION OF 5-HT AND CAPSAICIN IN ANAESTHETIZED RATS: A COMPARISON OF MECHANISMS" LUNG, vol. 162, no. 3, 1984, pages 153-163, XP008010417 * |
MITCHELL H W: "ANALYSIS BY MICROCOMPUTER OF THE EFFECT OF CAPSAICIN ON PULMONARY MECHANICS IN THE RAT AND GUINEA-PIG" ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE, DOIN, PARIS, BE, vol. 275, no. 2, juin 1985 (1985-06), pages 279-286, XP008021979 ISSN: 0301-4533 * |
PALECEK F ET AL: "Reflex responses to capsaicin: intravenous, aerosol, and intratracheal administration." JOURNAL OF APPLIED PHYSIOLOGY (BETHESDA, MD.: 1985) UNITED STATES OCT 1989, vol. 67, no. 4, octobre 1989 (1989-10), pages 1428-1437, XP008022531 ISSN: 8750-7587 * |
RAINS C ET AL: "TOPICAL CAPSAICIN A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN POST-HERPETIC NEURALGIA, DIABETIC NEUROPATHY AND OSTEOARTHRITIS" DRUGS AND AGING, ADIS INTERNATIONAL LTD, NZ, vol. 7, no. 4, 1995, pages 317-328, XP000604002 ISSN: 1170-229X * |
STJAERNE P ET AL: "LOCAL CAPSAICIN TREATMENT OF THE NASAL MUCOSA REDUCES SYMPTOMS IN PATIENTS WITH NONALLERGIC NASAL HYPERREACTIVITY" AMERICAN JOURNAL OF RHINOLOGY, OCEANSIDE PUBLICATIONS, PROVIDENCE, RI, US, vol. 5, no. 4, 1 juillet 1991 (1991-07-01), pages 145-151, XP000603517 ISSN: 1050-6586 * |
SZALLASI A ET AL: "VANILLOID (CAPSAICIN) RECEPTORS AND MECHANISMS" PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, vol. 51, no. 2, 1999, pages 159-211, XP001105620 ISSN: 0031-6997 * |
VIRUS R M ET AL: "PHARMACOLOGIC ACTIONS OF CAPSAICIN: APPARENT INVOLVEMENT OF SUBSTANCE P AND SEROTONIN" LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 25, no. 15, 8 octobre 1979 (1979-10-08), pages 1273-1283, XP000604075 ISSN: 0024-3205 * |
WOLF G ET AL: "[NDERUNGEN DES NASALEN VOLUMSSTROMES NACH LOKALER APPLIKATION DES NEUROPEPTIDES SUBSTANZ-P UND VON CAPSAICIN" LARYNGOLOGIE RHINOLOGIE OTOLOGIE UND IHRE GRENZGEBIETE VEREINIGT MIT MONATSSCHRIFT F]R OHRENHEILKUNDE, THIEME, STUTTGART, DE, vol. 66, no. 8, 1987, pages 412-415, XP000603410 ISSN: 0340-1588 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007047575A2 (fr) * | 2005-10-14 | 2007-04-26 | The Board Of Trustees Of The University Of Illinois | Traitements pharmacologiques contre des troubles du sommeil |
WO2007047575A3 (fr) * | 2005-10-14 | 2007-07-12 | Univ Illinois | Traitements pharmacologiques contre des troubles du sommeil |
EP2138054A1 (fr) | 2008-06-26 | 2009-12-30 | Léon Cariel | Extrait de plante pour la prévention ou le traitement du ronflement et/ou de l'apnée du sommeil |
FR2932987A1 (fr) * | 2008-06-26 | 2010-01-01 | Lmd | Extrait de plante pour la prevention ou le traitement du ronflement et/ou de l'apnee du sommeil |
Also Published As
Publication number | Publication date |
---|---|
AU2003244710A8 (en) | 2003-10-08 |
WO2003080036A3 (fr) | 2004-02-19 |
US20050118287A1 (en) | 2005-06-02 |
FR2837390A1 (fr) | 2003-09-26 |
AU2003244710A1 (en) | 2003-10-08 |
WO2003080036B1 (fr) | 2004-04-15 |
EP1487425A2 (fr) | 2004-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008215743B2 (en) | A composition for selective serotonin reuptake inhibition and process thereof | |
JP5602346B2 (ja) | ユーカリ抽出物の調製方法 | |
EP1014927B1 (fr) | Utilisation des shogaols et des gingerols pour la preparation de compositions deodorantes | |
JP3968405B2 (ja) | 抗アレルギー剤 | |
JP4693964B2 (ja) | 新規摂食抑制剤 | |
WO2003080036A2 (fr) | Utilisation d'un vanilloide comme anti-ronflement | |
TWI336624B (en) | Use of a potent product extracted from rhizomes of zingiber officinale in treating a disease associated with helicobacter pylori | |
JP4974553B2 (ja) | アセトアルデヒド代謝促進剤 | |
FR2821553A1 (fr) | Utilisation d'un ou plusieurs shogaol (s) en tant qu'aphrodisiaque | |
JP4325908B2 (ja) | 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物 | |
KR20040101598A (ko) | 생약자원으로부터 얻은 비만 치료 및/또는 예방 활성분획조성물 | |
WO2021246200A1 (fr) | Agent de suppression de l'atrophie musculaire | |
CA2459176A1 (fr) | Composition orale comprenant un extrait d'ecorce d'albizzia myriophylla | |
JP4328514B2 (ja) | 抗アレルギー剤 | |
JPH11302181A (ja) | 抗肥満症剤 | |
JP2000256204A (ja) | ノコギリヤシ油組成物 | |
JP4673474B2 (ja) | 新規肝障害抑制剤 | |
JP2021063018A (ja) | 神経変性疾患の予防剤及び/又は治療剤 | |
JP5066394B2 (ja) | ゲンクワニン5−O−β−プリメベロシドの抽出方法 | |
CA2710996A1 (fr) | 5-[1'-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h-cyclopropa[a]naphtalen-4-yl)-3'-methylbutyl]-2,4,6-trihydroxy-1,3-benzenedicarboxaldehyde en tant que medicaments | |
JP2002105017A (ja) | 新規肝障害抑制剤 | |
JP2001010968A (ja) | 新規肝障害抑制剤 | |
JP2001072599A (ja) | 新規肝障害抑制剤 | |
WO2018172380A1 (fr) | Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate | |
KR20020085507A (ko) | 3,4-디카페오일퀴닌 산의 제조 방법 및 콜레스테롤저하제로서의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
B | Later publication of amended claims |
Effective date: 20031217 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10509048 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003738193 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003738193 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003738193 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |